Category: Press Releases

Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria
Read More

Genprex Retains Addison Whitney for Drug Nomenclature Branding

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of
Read More

Genprex Collaborators Report Positive TUSC2 and Checkpoint Blockade Preclinical Data at the 2019 AACR Annual Meeting

Genprex reported that its collaborators from The University of Texas MD Anderson Cancer Center presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019.

Read More

Genprex Provides Clinical, Corporate, and Financial Update for the Year Ending December 31, 2018

Genprex today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission.

Read More

Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

Genprex today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.

Read More

Genprex Strengthens Senior Team and Continues to Advance Operations

Genprex announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.

Read More

Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

Genprex announced today the appointment of John N. Bonfiglio, PhD, to the company’s Board of Directors.

Read More

Genprex to Present at NobleConXV in Fort Lauderdale, Florida

Noble Capital Markets' Fifteenth Annual Investor / Equity Conference

Read More

Genprex to Present at Biotech Showcase™ 2019 in San Francisco

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019.

Read More

Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2018-- Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019.

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link